Skip to main content
ZNTL
NASDAQ Life Sciences

Zentalis Doses First Patient in Phase 3 ASPENOVA Trial for Ovarian Cancer Drug Azenosertib

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$4
Mkt Cap
$283.724M
52W Low
$1.13
52W High
$6.95
52W Position info
254% above low
Off High info
42% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

ZNTL has more than doubled off its 52-week low of $1.13.

Summary

Zentalis Pharmaceuticals announced the dosing of the first patient in its Phase 3 ASPENOVA clinical trial for azenosertib, targeting Cyclin E1-positive platinum-resistant ovarian cancer.


Key Events · Product Development and Regulatory · ZNTL

  • Phase 3 Trial Initiation

    Zentalis Pharmaceuticals announced the dosing of the first patient in the Phase 3 ASPENOVA clinical trial evaluating azenosertib for Cyclin E1-positive platinum-resistant ovarian cancer (PROC).

  • Confirmatory Trial for Full Approval

    The ASPENOVA trial is a randomized, confirmatory study designed to support full approval of azenosertib, enrolling approximately 420 patients and comparing azenosertib monotherapy to standard-of-care chemotherapy.

  • Dual Regulatory Strategy

    This Phase 3 trial is part of a dual-track regulatory strategy, complementing the ongoing DENALI Phase 2 trial which is intended to support accelerated approval with a topline readout expected by year-end 2026.

  • Addressing Unmet Medical Need

    Azenosertib is an investigational first-in-class WEE1 inhibitor targeting Cyclin E1-positive PROC, a biomarker-selected population with significant unmet medical needs.


Analysis · ZNTL · Life Sciences

This filing marks a critical advancement for Zentalis Pharmaceuticals as it initiates a pivotal Phase 3 clinical trial for its lead drug candidate, azenosertib. Dosing the first patient in the ASPENOVA trial is a significant milestone, moving the potential first-in-class WEE1 inhibitor closer to market. The trial is designed to support full FDA approval for Cyclin E1-positive platinum-resistant ovarian cancer, an area with high unmet medical need. This Phase 3 initiation, alongside the ongoing DENALI Phase 2 trial for accelerated approval, demonstrates a robust and aggressive regulatory strategy, which is highly positive for a clinical-stage biotech company.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ZNTL was trading at $4.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $283.7M. The 52-week trading range was $1.13 to $6.95. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ZNTL - Latest Insights

ZNTL
Nov 09, 2026, 4:08 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.74
Real-time Price: $1.42 info
Change: -$0.325 (-19%) info
Market Cap: $139.046M info
ZNTL
Oct 23, 2026, 10:15 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.31
Real-time Price: $1.42 info
Change: -$0.895 (-39%) info
Market Cap: $139.046M info
ZNTL
Oct 19, 2026, 2:31 PM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $2.29
Real-time Price: $1.42 info
Change: -$0.870 (-38%) info
Market Cap: $139.046M info
ZNTL
Oct 18, 2026, 6:11 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $2.11
Real-time Price: $1.42 info
Change: -$0.695 (-33%) info
Market Cap: $139.046M info
ZNTL
Aug 19, 2026, 6:11 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $3.82
Real-time Price: $1.42 info
Change: -$2.41 (-63%) info
Market Cap: $139.046M info